DR. LYNNETTE NIEMAN, M.D.
Osteopathic Medicine at Old Georgetown Rd, Bethesda, MD

License number
Maryland 142923
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
9309 Old Georgetown Rd, Bethesda, MD 20814
Phone
(301) 493-2400
(301) 496-8935
(301) 402-0884 (Fax)

Organization information

See more information about LYNNETTE NIEMAN at bizstanding.com

Lynnette Nieman MD

10 Ctr Dr, Bethesda, MD 20892

Industry:
Internist
Phone:
(301) 496-8935 (Phone)
Lynnette Kaye Nieman

Professional information

Lynnette Nieman Photo 1

Dr. Lynnette Nieman, Bethesda MD - MD (Doctor of Medicine)

Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
VALID FOR US CIVIL SERVICE EMPLOYEE ON
10 Ctr Dr, Bethesda 20892
(301) 496-0207 (Phone)
9309 Old Georgetown Rd, Bethesda 20814
(301) 493-2400 (Phone)
MOBILE MEDICAL CARE INC
9309 Old Georgetown Rd, Bethesda 20814
(301) 493-2400 (Phone)
FEDERAL GOVERNMENT RESEARCH FACILITY
10 Ctr Dr SUITE 10, Bethesda 20892
(301) 496-1434 (Phone), (301) 402-0380 (Fax)
Certifications:
Diabetes, Metabolism & Endocrinology, 2010, Internal Medicine, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
U Of Buffalo SUNY Sch Of Med & Biomedical Sci
Graduated: 1978
SUNY Buffalo Hosp
Natl Inst Hlth


Lynnette Nieman Photo 2

Lynnette Nieman, Bethesda MD

Specialties:
Endocrinologist
Address:
9309 Old Georgetown Rd, Bethesda, MD 20814


Lynnette Nieman Photo 3

Method For Treating Uterine Fibroids

US Patent:
8299050, Oct 30, 2012
Filed:
Jan 29, 2008
Appl. No.:
12/021610
Inventors:
Lynnette Nieman - Bethesda MD, US
André Ulmann - Paris, FR
Diana Blithe - Silver Spring MD, US
Erin Gainer - Paris, FR
Assignee:
Laboratoire HRA-Pharma - Paris
The United States of America, as represented by the Secretary, Department of Health and Human Services - Bethesda MD
International Classification:
A61K 31/56
US Classification:
514178
Abstract:
The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.